ALMS earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -15.08. Updated 2026-07-23.
Alumis (ALMS) Research Hub
Alumis (ALMS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 9.18 USD (-6.33%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.08, market cap 3.52B. This hub links to the full technical, earnings and options research available for ALMS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.18 USD (-6.33%) |
| 52-week range | 8.75 USD – 30.77 USD |
| Trend regime | Range |
| 14-day RSI | 12.8 (Oversold) |
| Trailing P/E | -15.08 |
| Market cap | 3.52B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ALMS
Covered Call on ALMS: how it works, illustrative setup around the real 9.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALMS: how it works, illustrative setup around the real 9.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALMS: how it works, illustrative setup around the real 9.18 USD price, max profit/loss, breakeven and when to use it. Educational.
ALMS technical analysis: range, last 9.18 USD, RSI 12.8, 52w range 8.75 USD–30.77 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALMS in?
Alumis (ALMS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALMS in an uptrend or downtrend?
As of 2026-09-11, ALMS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALMS's trailing P/E ratio?
ALMS's trailing P/E is -15.08, with a market cap of 3.52B. See the earnings research page for full valuation detail.
When does ALMS next report earnings?
ALMS is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.7 USD.